Feedback

Vasyl Khmelnytsky and partners invest $42 mln in Biopharma blood processing plant

The facility will produce blood products like Albumin, Bioven and Immunoglobulin that help treat diseases caused by immunodeficiency
17:14, 20 July 2018

Open source

Bila Tserkva city is a home to the CIS first plasma fractionation plant operated by Biopharma pharmaceutical company and co-owned by Vasyl Khmelnytsky.

The plant was built in a record-breaking short period of 1.3 years. Mr. Khmelnytsky and his partners invested $42 million in the research and production facility.

Built with contributions of Linde Engineering’s experts (Germany), the Biopharma plant has an area of five hectares and operates a pharmaceutical factory, an R&D center, a special laboratory, the raw materials and finished products warehouses, and power systems.

Biopharma spokespersons say, the plant covers the needs of the domestic market and is intensively tapping into foreign markets, particularly Asia, the Middle East and Africa. Last May, the Biopharma delegation visited some Latin American countries — Chile, Argentina, Peru, Bolivia and Ecuador — which are also promising and emerging markets.

Related: Sales of pharmaceuticals in Ukraine grow by 19% in 2017

Late in 2016, Biopharma started the third stage of the construction – the plant for blood plasma fractionation. According to Vasyl Khmelnytsky, after launch, the facility will produce blood products like Albumin, Bioven and Immunoglobulin that help treat diseases caused by immunodeficiency.

"This will revolutionize the Ukrainian pharmaceutical industry," Khmelnytsky Vasyl stated.

Related: European risks for the Ukrainian pharmaceutical market

Topics:
Система Orphus

If you find an error, highlight the desired text and press Ctrl + Enter, to tell about it

Comments
see more